Several of the proinflammatory peptides involved in rheumatoid arthritis pathogenesis, including peptides induced downstream of tumor necrosis factor-alpha as well as the monocyte/T cell-attracting chemokines RANTES and stromal cell-derived factor (SDF)-1alpha and the neuropeptides vasoactive intestinal peptide (VIP) and substance P, have their biological half-lives controlled by dipeptidyl peptidase IV (DPPIV). Proteolysis by DPPIV regulates not only the half-life but also receptor preference and downstream signaling. In this article, we examine the role of DPPIV homologs, including CD26, the canonical DPPIV, and their substrates in the pathogenesis of rheumatoid arthritis. The differing specific activities of the DPPIV family members and their differential inhibitor response provide new insights into therapeutic design.

Laboratory of Cancer Cell Biology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpe S. Proline motifs in peptides and their biological processing. Faseb J. 1995;9:736–744. PubMed

Busek P, Malik R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 2004;36:408–421. doi: 10.1016/S1357-2725(03)00262-0. PubMed DOI

Mentlein R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24. doi: 10.1016/S0167-0115(99)00089-0. PubMed DOI

Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol. 2003;82:53–73. doi: 10.1078/0171-9335-00302. PubMed DOI

Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol. 2003;33:1519–1527. doi: 10.1002/eji.200323469. PubMed DOI

Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol. 1994;370:411–416. PubMed

Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, Cronstein BN. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 2003;48:240–247. doi: 10.1002/art.10712. PubMed DOI

Nakamachi Y, Koshiba M, Nakazawa T, Hatachi S, Saura R, Kurosaka M, Kusaka H, Kumagai S. Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum. 2003;48:668–674. doi: 10.1002/art.10956. PubMed DOI

Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta. 2001;1550:107–116. PubMed

Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26) J Biol Chem. 1995;270:14107–14114. doi: 10.1074/jbc.270.23.14107. PubMed DOI

Friedrich D, Kuhn-Wache K, Hoffmann T, Demuth HU. Isolation and characterization of attractin-2. Adv Exp Med Biol. 2003;524:109–113. PubMed

Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-pepti-dase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem. 1998;273:7222–7227. doi: 10.1074/jbc.273.13.7222. PubMed DOI

Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA. 1998;95:6331–6336. doi: 10.1073/pnas.95.11.6331. PubMed DOI PMC

Choy EHS, Kingsley GH, Panayi GS. Immunotherapies: T cell, B cell and complement. In: Hochberg MC, Silman AJ, Smolen J, Weinblatt ME, Weisman MH, editor. Rheumatology. 3. Edinburgh: Mosby; 2003. pp. 449–460.

Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2004;22:335–338. PubMed

Yan S, Sloane BF. Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem. 2003;384:845–854. doi: 10.1515/BC.2003.095. PubMed DOI

Gonzalez-Gronow M, Gawdi G, Pizzo SV. Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. J Biol Chem. 1994;269:4360–4366. PubMed

Casanova JE, Mishumi Y, Ikehara Y, Hubbard AL, Mostov KE. Direct apical sorting of rat liver dipeptidylpeptidase IV expressed in Madin-Darby canine kidney cells. J Biol Chem. 1991;266:24428–24432. PubMed

Riemann D, Hansen GH, Niels-Christiansen L, Thorsen E, Immerdal L, Santos AN, Kehlen A, Langner J, Danielsen EM. Caveolae/lipid rafts in fibroblast-like synoviocytes: ectopepti-dase-rich membrane microdomains. Biochem J. 2001;354:47–55. doi: 10.1042/0264-6021:3540047. PubMed DOI PMC

Buhling F, Junker U, Reinhold D, Neubert K, Jager L, Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett. 1995;45:47–51. doi: 10.1016/0165-2478(94)00230-O. PubMed DOI

Buhling F, Kunz D, Reinhold D, Ulmer AJ, Ernst M, Flad HD, Ansorge S. Expression and functional role of dipeptidyl pepti-dase IV (CD26) on human natural killer cells. Nat Immun. 1994;13:270–279. PubMed

Jackman HL, Tan F, Schraufnagel D, Dragovic T, Dezso B, Becker RP, Erdos EG. Plasma membrane-bound and lysosomal pepti-dases in human alveolar macrophages. Am J Respir Cell Mol Biol. 1995;13:196–204. PubMed

Bertotto A, Gerli R, Spinozzi F, Muscat C, Fabietti GM, Crupi S, Castellucci G, De Benedictis FM, De Giorgi G, Britta R, et al. CD26 surface antigen expression on peripheral blood T lymphocytes from children with Down's syndrome (trisomy 21) Scand J Immunol. 1994;39:633–636. PubMed

De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today. 1999;20:367–375. doi: 10.1016/S0167-5699(99)01486-3. PubMed DOI

Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schloss-man SF, Morimoto C. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA. 1994;91:3082–3086. PubMed PMC

Ohnuma K, Munakata Y, Ishii T, Iwata S, Kobayashi S, Hosono O, Kawasaki H, Dang NH, Morimoto C. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol. 2001;167:6745–6755. PubMed

Ikushima H, Munakata Y, Iwata S, Ohnuma K, Kobayashi S, Dang NH, Morimoto C. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol. 2002;215:106–110. doi: 10.1016/S0008-8749(02)00010-2. PubMed DOI

Kobayashi H, Hosono O, Mimori T, Kawasaki H, Dang NH, Tanaka H, Morimoto C. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol. 2002;29:1858–1866. PubMed

Krepela E, Kasafirek E, Vicar J, Kraml J. An assay of dipeptidyl peptidase IV activity in human serum and serum of pregnant women with glycyl-L-proline-1-naphthylamide and other glycyl-L-proline-arylamides as substrates. Physiol Bohemoslov. 1983;32:334–345. PubMed

Sedo A, Malik R, Votruba M, Hanic T, Hanic O. Serum dipeptidyl peptidase IV activities in Czernobyl zone inhabitants exposed to the power-station catastrophe. Eur J Clin Chem Clin Biochem. 1996;34:447–448. PubMed

Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpe S, Kupiec-Weglinski JW. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 1997;63:1495–1500. doi: 10.1097/00007890-199705270-00021. PubMed DOI

Hagihara M, Ohhashi M, Nagatsu T. Activities of dipeptidyl pep-tidase II and dipeptidyl peptidase IV in mice with lupus ery-thematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis. Clin Chem. 1987;33:1463–1465. PubMed

Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int. 2001;21:69–74. doi: 10.1007/s002960100134. PubMed DOI

Kullertz G, Boigk J. Dipeptidyl peptidase IV activity in the serum and synovia of patients with rheumatoid arthritis. Z Rheumatol. 1986;45:52–56. PubMed

Scholzova E, Sedova L, Mares V, Balaziova E, Vlasicova K, Nytrova P, Sevcik J, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) – the novel players in pathogenesis of rheumatoid and psoriatic arthritides. Eur J Biochem. 2004;271:104–105.

Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol. 2001;19:673–680. PubMed

Mantle D, Falkous G, Walker D. Quantification of protease activities in synovial fluid from rheumatoid and osteoarthritis cases: comparison with antioxidant and free radical damage markers. Clin Chim Acta. 1999;284:45–58. doi: 10.1016/S0009-8981(99)00055-8. PubMed DOI

Cordero OJ, Salgado FJ, Vinuela JE, Nogueira M. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology. 1997;197:522–533. PubMed

Salgado FJ, Vela E, Martin M, Franco R, Nogueira M, Cordero OJ. Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine. 2000;12:1136–1141. doi: 10.1006/cyto.1999.0643. PubMed DOI

Cordero OJ, Salgado FJ, Fernandez-Alonso CM, Herrera C, Lluis C, Franco R, Nogueira M. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. J Leukoc Biol. 2001;70:920–930. PubMed

Sorrell JM, Brinon L, Baber MA, Caplan AI. Cytokines and gluco-corticoids differentially regulate APN/CD13 and DPPIV/CD26 enzyme activities in cultured human dermal fibroblasts. Arch Dermatol Res. 2003;295:160–168. doi: 10.1007/s00403-003-0417-4. PubMed DOI

Yamabe T, Takakura K, Sugie K, Kitaoka Y, Takeda S, Okubo Y, Teshigawara K, Yodoi J, Hori T. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology. 1997;91:151–158. doi: 10.1046/j.1365-2567.1997.00230.x. PubMed DOI PMC

Brezinschek RI, Lipsky PE, Galea P, Vita R, Oppenheimer-Marks N. Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity. J Immunol. 1995;154:3062–3077. PubMed

Masuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol. 1992;148:1367–1374. PubMed

Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 2002;277:29231–29241. doi: 10.1074/jbc.M202770200. PubMed DOI

Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. 2003;22:259–269. doi: 10.1023/A:1023055600919. PubMed DOI

Mizokami A, Eguchi K, Kawakami A, Ida H, Kawabe Y, Tsukada T, Aoyagi T, Maeda K, Morimoto C, Nagataki S. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. J Rheumatol. 1996;23:2022–2026. PubMed

McInnes IB, Liew FY. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today. 1998;19:75–79. doi: 10.1016/S0167-5699(97)01205-X. PubMed DOI

Gerli R, Muscat C, Bertotto A, Bistoni O, Agea E, Tognellini R, Fiorucci G, Cesarotti M, Bombardieri S. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin Immunol Immunopathol. 1996;80:31–37. doi: 10.1006/clin.1996.0091. PubMed DOI

Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol. 1996;156:1714–1721. PubMed

Sedova L, Scholzova E, Vlasicova K, Stolfa J, Krystufkova O, Ruz-ickova S, Sevcik J, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) in blood and synovial fluid mononuclear cells of patients with rheumatoid and pso-riatic arthritis. Ann Rheum Dis. 2004;63(Suppl I):124.

Fujita K, Hirano M, Ochiai J, Funabashi M, Nagatsu I, Nagatsu T, Sakakibara S. Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus. Clin Chim Acta. 1978;88:15–20. doi: 10.1016/0009-8981(78)90142-0. PubMed DOI

Bathon JM, Proud D, Mizutani S, Ward PE. Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides. J Clin Invest. 1992;90:981–991. PubMed PMC

Kamori M, Hagihara M, Nagatsu T, Iwata H, Miura T. Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis. Biochem Med Metab Biol. 1991;45:154–160. doi: 10.1016/0885-4505(91)90016-E. PubMed DOI

Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A, Grouzmann E. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 2005;166:433–442. PubMed PMC

Duke-Cohan JS, Tang W, Schlossman SF. Attractin: a cub-family protease involved in T cell-monocyte/macrophage interactions. Adv Exp Med Biol. 2000;477:173–185. PubMed

Iwaki-Egawa S, Watanabe Y, Matsuno H. Correlations between matrix metalloproteinase-9 and adenosine deaminase isozymes in synovial fluid from patients with rheumatoid arthritis. J Rheumatol. 2001;28:485–489. PubMed

Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261:466–469. PubMed

Senten K, Van Der Veken P, De Meester I, Lambeir AM, Scharpe S, Haemers A, Augustyns K. Gamma-amino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors. J Med Chem. 2004;47:2906–2916. doi: 10.1021/jm031122f. PubMed DOI

Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem. 1989;35:1016–1018. PubMed

Tang W, Gunn TM, McLaughlin DF, Barsh GS, Schlossman SF, Duke-Cohan JS. Secreted and membrane attractin result from alternative splicing of the human ATRN gene. Proc Natl Acad Sci USA. 2000;97:6025–6030. doi: 10.1073/pnas.110139897. PubMed DOI PMC

Liao H, Wu J, Kuhn E, Chin W, Chang B, Jones MD, O'Neil S, Clauser KR, Karl J, Hasler F, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004;50:3792–3803. doi: 10.1002/art.20720. PubMed DOI

Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA. 2000;97:6874–6879. doi: 10.1073/pnas.120069197. PubMed DOI PMC

Gutierrez MA, Garcia ME, Rodriguez JA, Mardonez G, Jacobelli S, Rivero S. Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol. 1999;26:277–281. PubMed

Masi AT, Bijlsma JW, Chikanza IC, Pitzalis C, Cutolo M. Neuroen-docrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives. Semin Arthritis Rheum. 1999;29:65–81. doi: 10.1016/S0049-0172(99)80039-0. PubMed DOI

Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897–901. doi: 10.1038/29795. PubMed DOI

Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S. Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol. 2001;19:715–720. PubMed

Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988;241:1218–1221. PubMed

Lambert N, Lescoulie PL, Yassine-Diab B, Enault G, Mazieres B, De Preval C, Cantagrel A. Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes. Clin Exp Immunol. 1998;113:269–275. doi: 10.1046/j.1365-2249.1998.00621.x. PubMed DOI PMC

Inoue H, Shimoyama Y, Hirabayashi K, Kajigaya H, Yamamoto S, Oda H, Koshihara Y. Production of neuropeptide substance P by synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis. Neurosci Lett. 2001;303:149–152. doi: 10.1016/S0304-3940(01)01713-X. PubMed DOI

Hernanz A, Medina S, de Miguel E, Martin-Mola E. Effect of calci-tonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept. 2003;115:19–24. doi: 10.1016/S0167-0115(03)00127-7. PubMed DOI

Yokoyama MM, Fujimoto K. Role of lymphocyte activation by substance P in rheumatoid arthritis. Int J Tissue React. 1990;12:1–9. PubMed

Covas MJ, Pinto LA, Pereira Da Silva JA, Victorino RM. Effects of the neuropeptide, substance P, on lymphocyte proliferation in rheumatoid arthritis. J Int Med Res. 1995;23:431–438. PubMed

Covas MJ, Pinto LA, Victorino RM. Effects of substance P on human T cell function and the modulatory role of peptidase inhibitors. Int J Clin Lab Res. 1997;27:129–134. PubMed

Zukowska Z, Pons J, Lee EW, Li L. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol. 2003;81:89–94. doi: 10.1139/y03-006. PubMed DOI

Schwarz H, Villiger PM, von Kempis J, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol. 1994;51:53–61. doi: 10.1016/0165-5728(94)90128-7. PubMed DOI

Silva AP, Cavadas C, Baisse-Agushi B, Spertini O, Brunner HR, Grouzmann E. NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC. Regul Pept. 2003;116:71–79. doi: 10.1016/S0167-0115(03)00191-5. PubMed DOI

Straub RH, Mayer M, Kreutz M, Leeb S, Scholmerich J, Falk W. Neurotransmitters of the sympathetic nerve terminal are powerful chemoattractants for monocytes. J Leukoc Biol. 2000;67:553–558. PubMed

Appelgren A, Appelgren B, Eriksson S, Kopp S, Lundeberg T, Nylander M, Theodorsson E. Neuropeptides in temporo-mandibular joints with rheumatoid arthritis: a clinical study. Scand J Dent Res. 1991;99:519–521. PubMed

Dimitrijevic M, Stanojevic S, Vujic V, Kovacevic-Jovanovic V, Beck-Sickinger A, Demuth H, von Horsten S. Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26) J Neuroimmunol. 2002;129:35–42. doi: 10.1016/S0165-5728(02)00173-X. PubMed DOI

Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vazquez JJ, Gijon-Banos J, Hernanz A. Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett. 1994;170:251–254. doi: 10.1016/0304-3940(94)90331-X. PubMed DOI

Wang F, Millet I, Bottomly K, Vignery A. Calcitonin gene-related peptide inhibits interleukin 2 production by murine T lymphocytes. J Biol Chem. 1992;267:21052–21057. PubMed

Juarranz MG, Santiago B, Torroba M, Gutierrez-Canas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL, et al. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) 2004;43:416–422. doi: 10.1093/rheumatology/keh061. PubMed DOI

Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoac-tive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001;7:563–568. doi: 10.1038/87887. PubMed DOI

Del Rio M, De la Fuente M. Stimulation of natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) activities in murine leukocytes by bombesin-related peptides requires the presence of adherent cells. Regul Pept. 1995;60:159–166. doi: 10.1016/0167-0115(95)00125-5. PubMed DOI

Hill DJ, McDonald TJ. Mitogenic action of gastrin-releasing polypeptide on isolated epiphyseal growth plate chondro-cytes from the ovine fetus. Endocrinology. 1992;130:2811–2819. doi: 10.1210/en.130.5.2811. PubMed DOI

Bertazzolo N, Punzi L, Stefani MP, Cesaro G, Pianon M, Finco B, Todesco S. Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions. 1994;41:90–92. doi: 10.1007/BF01986402. PubMed DOI

Partsch G, Wagner E, Leeb BF, Broll H, Dunky A, Smolen JS. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis. 1998;57:691–693. PubMed PMC

Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic syn-ovium. J Rheumatol. 1998;25:1544–1552. PubMed

Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:202–213. doi: 10.1093/rheumatology/38.3.202. PubMed DOI

Hoffmann T, Faust J, Neubert K, Ansorge S. Dipeptidyl pepti-dase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. 1993;336:61–64. doi: 10.1016/0014-5793(93)81609-4. PubMed DOI

Bauvois B, Sanceau J, Wietzerbin J. Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor-alpha. Eur J Immunol. 1992;22:923–930. PubMed

Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest. 2004;114:471–474. doi: 10.1172/JCI200422651. PubMed DOI PMC

Konig A, Krenn V, Toksoy A, Gerhard N, Gillitzer R. Mig, GRO alpha and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows Arch. 2000;436:449–458. doi: 10.1007/s004280050472. PubMed DOI

Loetscher P, Moser B. Homing chemokines in rheumatoid arthritis. Arthritis Res. 2002;4:233–236. doi: 10.1186/ar412. PubMed DOI PMC

Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol. 1995;101:398–407. PubMed PMC

Wang CR, Liu MF. Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol. 2003;132:371–378. doi: 10.1046/j.1365-2249.2003.02126.x. PubMed DOI PMC

Guan E, Wang J, Norcross MA. Amino-terminal processing of MIP-1beta/CCL4 by CD26/dipeptidyl-peptidase IV. J Cell Biochem. 2004;92:53–64. doi: 10.1002/jcb.20041. PubMed DOI

Katschke KJ, Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, Ponath P, Park CC, Pope RM, Koch AE. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. 2001;44:1022–1032. doi: 10.1002/1529-0131(200105)44:5<1022::AID-ANR181>3.0.CO;2-N. PubMed DOI

Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-pep-tidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209–294. PubMed

Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood. 2001;98:3554–3561. doi: 10.1182/blood.V98.13.3554. PubMed DOI

Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y, Negishi M, Ide H, Miyaoka H, Uchida H, et al. A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther. 2003;5:R74–81. doi: 10.1186/ar616. PubMed DOI PMC

Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol. 2001;98:39–45. doi: 10.1006/clim.2000.4957. PubMed DOI

Bradfield PF, Amft N, Vernon-Wilson E, Exley AE, Parsonage G, Rainger GE, Nash GB, Thomas AM, Simmons DL, Salmon M, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum. 2003;48:2472–2482. doi: 10.1002/art.11219. PubMed DOI

Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seis-dedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol. 2000;165:3423–3429. PubMed

Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, Franco R. Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem. 2001;276:19532–19539. doi: 10.1074/jbc.M004586200. PubMed DOI

Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, Obika S, Imanishi T, Tsujimura T, Hamaoka T, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol. 2002;32:2124–2132. doi: 10.1002/1521-4141(200208)32:8<2124::AID-IMMU2124>3.0.CO;2-S. PubMed DOI

Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, Schlossman SF, Morimoto C. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol. 1999;11:417–426. doi: 10.1093/intimm/11.3.417. PubMed DOI

Wiedeman PE, Trevillyan JM. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs. 2003;4:412–420. PubMed

Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalo-myelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol. 2001;166:2041–2048. PubMed

Korom S, De Meester I, Schmidbauer G, Pratschke J, Brendel MD, Durinx C, Schwemmle K, Haemers A, Scharpe S, Kupiec-Weglinski JW. Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity. Transplant Proc. 1999;31:778. doi: 10.1016/S0041-1345(98)02069-7. PubMed DOI

Reinhold D, Hemmer B, Gran B, Steinbrecher A, Brocke S, Kahne T, Wrenger S, Born I, Faust J, Neubert K, et al. Dipeptidyl pepti-dase IV (CD26): role in T cell activation and autoimmune disease. Adv Exp Med Biol. 2000;477:155–160. PubMed

Reinhold D, Bank U, Buhling F, Kahne T, Kunt D, Faust J, Neubert K, Ansorge S. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology. 1994;192:121–136. PubMed

Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipep-tidyl peptidase IV. Int J Immunopharmacol. 1997;19:15–24. doi: 10.1016/S0192-0561(97)00004-0. PubMed DOI

Tanaka S, Murakami T, Nonaka N, Ohnuki T, Yamada M, Sugita T. Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology. 1998;40:21–26. doi: 10.1016/S0162-3109(98)00014-9. PubMed DOI

Williams YN, Baba H, Hayashi S, Ikai H, Sugita T, Tanaka S, Miyasaka N, Kubota T. Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol. 2003;131:68–74. doi: 10.1046/j.1365-2249.2003.02020.x. PubMed DOI PMC

Williams YN, Sugita T, Nosaka Y, Kubota T. Suppression of fibroblast activity by an inhibitor of dipeptidyl peptidase IV: a possible therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:685. PubMed

Calvo CF, Chavanel G, Senik A. Substance P enhances IL-2 expression in activated human T cells. J Immunol. 1992;148:3498–3504. PubMed

Laurenzi MA, Persson MA, Dalsgaard CJ, Ringden O. Stimulation of human B lymphocyte differentiation by the neuropeptides substance P and neurokinin A. Scand J Immunol. 1989;30:695–701. PubMed

Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH. Glycosaminogly-can binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA. 2003;100:1885–1890. doi: 10.1073/pnas.0334864100. PubMed DOI PMC

Wollheim FA. Predictors of joint damage in rheumatoid arthritis. Apmis. 1996;104:81–93. PubMed

Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl. 2005;74:13–18. PubMed

Muscat C, Bertotto A, Agea E, Bistoni O, Ercolani R, Tognellini R, Spinozzi F, Cesarotti M, Gerli R. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol. 1994;98:252–256. PubMed PMC

Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity